UCSF Liver Center Seminar

August 8 | 9AM-10AM | PARNASSUS, S-214

INTRODUCING NEW LIVER CENTER MEMBER

Nicole Paulk, PhD

UCSF, Biochemistry and Biophysics

Engineering technologies for improving human liver gene and cell therapies

For patients seeking treatment for genetic liver diseases, the standard of care can often be invasive (e.g. liver transplantation) and temporary (e.g. enzyme replacement therapy). Gene and cell therapies are attractive alternatives as they can be non-invasive with long-term therapeutic benefits. However, the success of this new generation of translational hepatic therapies are critically dependent on efficiency, efficacy, safety and cost. In the Paulk lab we engineer new technologies to address these needs. We study sexually dimorphic proteomic and transcriptomic human liver signatures pre/post regeneration and viral infection, develop viral genome engineering platforms, design combinatorial gene therapies to improve targeting and reduce costs, and create new human liver mouse models to validate gene and cell therapies in human liver in vivo.

Host: Holger Willenbring, MD, PhD

Go to livercenter.ucsf.edu for a full list of upcoming events

UCSF University of California San Francisco | LIVER CENTER